2417135-66-9
Chemical Structure
Envudeucitinibum
Synonym(s): Envudeucitinib; ESK-001
- CAS No.: 2417135-66-9
- Formula:C22H18D6N6O3
- Molecular Weight:426.50
InChIKey: FKCATCQHVCOBCX-WFGJKAKNSA-N
SMILES: COC1=C(C2=NN(C([2H])([2H])[2H])C=N2)C=CC=C1NC3=CC(NC(C4CC4)=O)=NC=C3C(CC([2H])([2H])[2H])=O
Biological Activity: Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Envudeucitinibum | 99.56% | Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
JAK-IN-26 | 98.00% | JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC50=17.2 nM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ucpinar S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design. Clin Transl Sci. 2024 Dec;17(12):e70094. [Content Brief]
- [2]. Papp KA, et al. Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study. J Am Acad Dermatol. 2026;94(1):187-195. [Content Brief]
Keywords
